Order now

The CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex ValuPanel™ Reagents are separately delivered probes and primers for RT-PCR detection of the genetic sequences of SARS-CoV-2, influenza A, and influenza B viruses. For Research Use Only. Not for use in diagnostic procedures.

Key benefits

  • Fast delivery: Product in stock ships same or next business day
  • Gold standard quencher: From the trusted inventor and original source of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO protocols
  • Quality manufacture: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.

order now in the
new transaction portal

Item Sequence
Influenza A, FluSC2 Multiplex Fwd Primer 1 CAA GAC CAA TCY TGT CAC CTC TGA C
Influenza A, FluSC2 Multiplex Rev Primer 1 GCA TTY TGG ACA AAV CGT CTA CG
Influenza A, FluSC2 Multiplex Fwd Primer 2 CAA GAC CAA TYC TGT CAC CTY TGA C
Influenza A, FluSC2 Multiplex Rev Primer 2 GCA TTT TGG ATA AAG CGT CTA CG
Influenza A, FluSC2 Multiplex Probe FAM-TGC AGT CCT [Nova] CGC TCA CTG GGC ACG-BHQ-1
Influenza B, FluSC2 Multiplex Fwd Primer TCC TCA AYT CAC TCT TCG AGC G
Influenza B, FluSC2 Multiplex Rev Primer CGG TGC TCT TGA CCA AAT TGG
Influenza B, FluSC2 Multiplex Probe CIV-550-CCA ATT CGA [BHQ-1] GCA GCT GAA ACT GCG GTG-Spacer C3
SARS-CoV-2, FluSC2 Multiplex Fwd Primer CTG CAG ATT TGG ATG ATT TCT CC
SARS-CoV-2, FluSC2 Multiplex Rev Primer CCT TGT GTG GTC TGC ATG AGT TTA G
SARS-CoV-2, FluSC2 Multiplex Probe CAL Fluor Red 610-ATT GCA ACA [Nova] ATC CAT GAG CAG TGC TGA CTC-BHQ-2
Human RNase P Extraction Control Forward Primer AGA TTT GGA CCT GCG AGC G
Human RNase P Extraction Control Reverse Primer GAG CGG CTG TCT CCA CAA GT
Human RNase P, FluSC2 Multiplex Probe Quasar 670-TTC TGA CCT [Nova] GAA GGC TCT GCG CG-BHQ-2

Product info

The CDC Flu SC2 Multiplex ValuPanel consists of probes and primers delivered in individual tubes in dried format. The panel includes double-quenched probes using Black Hole Quencher™ (BHQ™) technology, which improves quenching efficiency compared to traditional end-labeled probes, while also improving signal release upon amplification.

The CDC Flu SC2 Multiplex ValuPanel comprises probes and primers based on the following genetic signatures:

  • SARS-CoV-2 nucleocapsid (N)

  • Influenza A virus matrix (M1)

  • Influenza B virus Nonstructural 2 (NS2)

  • Human RNase P (extraction control)

The oligonucleotide sequences were designed by the US Centers for Disease Control and Prevention (CDC) for use in the CDC Flu SC2 Multiplex Assay, a real-time RT-PCR test to diagnose infection caused by one of three viruses: SARS-CoV-2, influenza A, and influenza B. The CDC developed the CDC Flu SC2 Multiplex Assay to allow for ongoing influenza surveillance while also testing for SARS-CoV-2. The assay was granted Emergency Use Authorization (EUA) on July 2, 2020. Learn more about the CDC Flu SC2 Multiplex Assay.

The probes and primers described in the CDC Flu SC2 Multiplex Assay Instructions For Use are premixed, with the primers combined into one tube, and the probes combined into another tube. For detailed instructions of how to resuspend and premix the ValuPanel probes and primers, please see the quick guide.

order now in the
new transaction portal

Important note: The use of ROX normalisation is not compatible with this panel

Please be aware that master mixes containing ROX passive reference dye should not be used with this panel. This is because the probe for SARS-CoV-2 (cat. no SC2-FSC2-P) is modified with CAL Fluor Red 610 dye, which is detected in the same channel as ROX dye.

If your instrument requires ROX normalisation, please contact the Scientific Services Team for assistance with custom multiplex assay development.

The performance of LGC’s Flu SC2 ValuPanel is equivalent to that of the CDC Flu SC2 Multiplex Assay

Real-time RT-PCR results (Ct) demonstrate the equivalent performance of the LGC assay (Flu SC2 Multiplex ValuPanel) and the CDC assay (CDC Flu SC2 Multiplex Assay published in the U.S. FDA-authorized IFU LB-122 Rev 01 Effective Date: 21 September 2020). Across a range of target copy numbers (5, 50 and 500 copies), for each assay (InfA, InfB, SC2, and RP), the LGC assay chemistry reaches the detection threshold within +/- 1  cycle of the published CDC assay chemistry. 

Suggested probe and primer quantities to support 5,000 or 20,000 tests

Based on a 20 uL reaction volume with oligonucleotide concentrations as specified in the CDC Flu SC2 Multiplex Assay Instructions For Use (LB-122 Rev 01, effective 21 September 2020)

Resources

Recommended products

PCR reagents* including master mix and enzyme for SARS-CoV-2 assay development are also available

Item name  
sbeadex viral RNA purification kit View product
RapiDxFire 1-step RT-qPCR System View product

For a complete SARS-CoV-2 Quality Solution, consider the AccuPlex™ SARS-CoV-2 Verification Panel coupled with the AccuPlex™ SARS-CoV-2 Reference Material Kit from LGC SeraCare Life Sciences. The target sequence of interest is packaged into a stable non-infectious, and replication-deficient alphavirus particle and the products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Also includes negative materials targeting the human RNase P gene.

What do you require to develop your SARS-CoV-2 assay?

We offer probes and primers specific to Coronavirus as well as enzymes, master mix, and extraction capabilities.

Let’s discuss your needs

Related products

Item name  
2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2 View product
Charité 2019-nCoV BBQ-650 ValuPanel Reagents* View product
Charité 2019-nCoV BHQ ValuPanel Reagents* View product
US CDC 2019-nCoV ValuPanel Reagents* View product
Yale 2019-nCoV SalivaDirect ValuPanel Reagents* View product

 

*For Research Use Only. Not for use in diagnostic procedures.